How were Intec Pharma's earnings last quarter?

Intec Pharma Ltd (NASDAQ:NTEC) announced its quarterly earnings data on Monday, May, 17th. The biotechnology company reported ($3.84) earnings per share for the quarter, missing the consensus estimate of ($3.48) by $0.36.

When did Intec Pharma's stock split?

Shares of Intec Pharma reverse split on Tuesday, July 27th 2021. The 1-4 reverse split was announced on Tuesday, July 27th 2021. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, July 27th 2021. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split.

What other stocks do shareholders of Intec Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Intec Pharma investors own include SCYNEXIS (SCYX) , Inovio Pharmaceuticals (INO) , Dynavax Technologies (DVAX) , Nabriva Therapeutics (NBRV) , Onconova Therapeutics (ONTX) , Viking Therapeutics (VKTX) , Allena Pharmaceuticals (ALNA) , T2 Biosystems (TTOO) and Acasti Pharma (ACST) .

When did Intec Pharma IPO?

Intec Pharma (NTEC) raised $30 million in an IPO on Tuesday, August 4th 2015. The company issued 5,000,000 shares at a price of $6.00 per share. Maxim Group and Roth Capital Partners acted as the underwriters for the IPO.

NASDAQ:NTEC

Intec Pharma (NTEC) Stock Price, News & Analysis

→ Bitcoin Rockets To Record High But Buy THIS Instead (From Paradigm Press) (Ad)

Free NTEC Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: N/A
50-Day Range: $9.15
▼
$36.20
52-Week Range: N/A

Volume: 988,300 shs
Average Volume: 543,436 shs
Market Capitalization: $8.65 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Intec Pharma alerts:

Ad DTI

This company has increased its dividend every year for 54 years

There are three basic steps to building the Ultimate Dividend Portfolio. Step #1 is to Get The High Yields! So an index fund like the SPY, paying only 1.5% a year, isn’t going to cut it. But a company like Altria Group (MO) will.

Click here to get them (for Free).

About Intec Pharma Stock (NASDAQ:NTEC)

Intec Pharma Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of drugs based on proprietary Accordion Pill platform technology. Its Accordion Pill technology is an oral drug delivery system that is designed to improve the efficacy and safety of existing drugs and drugs under development by utilizing an efficient gastric retention and specific release mechanism. The company was founded by Zvika Joseph on October 23, 2000 and is headquartered in Jerusalem, Israel.

Ad DTI

This company has increased its dividend every year for 54 years

Click here to get them (for Free).

NTEC Stock News Headlines

March 15, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Indaptus Therapeutics Amid Positive Clinical and Financial Outlook

March 7, 2024 | markets.businessinsider.com

Buy Rating Affirmed on Indaptus Therapeutics as Decoy20 Advances in Phase 1 with Promising Developments

April 19, 2024 | Tips4Traders (Ad)

Uncover this 2024 Hidden Gem

Exclusive Report: Uncover a Hidden Investment Gem We’re excited to share a special report on one exceptional, publicly traded company. This company has achieved a remarkable 22+% just this year, outperforming the market and revealing the potential for significant gains.

February 18, 2024 | msn.com

Stocks to Watch Today: RVNL,Glenmark Pharma, PB Fintech,Sula Vineyards and more

February 2, 2024 | msn.com

Chhattisgarh education minister calls for expansion of central schools in the state

August 15, 2023 | markets.businessinsider.com

H.C. Wainwright Sticks to Its Buy Rating for Indaptus Therapeutics (INDP)

June 16, 2023 | finance.yahoo.com

NGENF - NervGen Pharma Corp.

May 12, 2023 | marketwatch.com

10-Q: INDAPTUS THERAPEUTICS, INC.

April 19, 2024 | DTI (Ad)

This company has increased its dividend every year for 54 years

May 10, 2023 | marketwatch.com

Fibromyalgia Treatment Market Research | 2023-2030

May 9, 2023 | marketwatch.com

Early Pregnancy Test Kit Market May Set Epic Growth Story Major Players – Abbott, Church & Dwight, SPD Swiss Precision Diagnostics GmbH

May 4, 2023 | marketwatch.com

Fibromyalgia Treatment Market Share, Size, Financial Summaries Analysis from 2023 to 2028

April 28, 2023 | marketwatch.com

Fibromyalgia Treatment Market Share by 2031

April 24, 2023 | ca.finance.yahoo.com

Intec Pharma Ltd (5NU.SG)

March 30, 2023 | marketwatch.com

Fibromyalgia Treatment Market Size, Share, Outlook and Forecast to 2031

March 18, 2023 | markets.businessinsider.com

Maxim Group Reaffirms Their Buy Rating on Indaptus Therapeutics (INDP)

March 2, 2023 | marketwatch.com

Fibromyalgia Treatment Market Forecast: An Analysis of Industry Trends for 2023-2028

February 19, 2023 | marketwatch.com

Global Parkinson’s Disease Treatment Market Opportunities, Business Statistics Research Report 2030 By VMReports

February 15, 2023 | marketwatch.com

Fibromyalgia Treatment Market Size 2023 With Over-All Dominated, Share Of Everywhere, Ease Of Access Of Solutions

January 30, 2023 | marketwatch.com

Syphilis Rapid Test Kit Market : Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2028

January 23, 2023 | marketwatch.com

Fibromyalgia Treatment Market Industry Updates, New Opportunities, Major Strategies, And Forecast 2028

December 29, 2022 | marketwatch.com

With 1.7% CAGR, Fibromyalgia Treatment Market 2023 Is Flourishing Around the World by 2028 | 116 Pages Report

December 21, 2022 | marketwatch.com

Fibromyalgia Treatment Market (New Report) to Witness A Pronounce Growth During 2023-2028 | 116 Pages Report

October 17, 2022 | marketwatch.com

Fibromyalgia Treatment Market Size in 2022 with Latest Report of 100 Pages & Business Forecast up to 2028 by Value Chain Analysis | No of Pages 100

August 28, 2022 | marketwatch.com

Fibromyalgia Treatment Market Size and Share 2022 Analysis Report by Industry Trends, Drivers, Applications, Sale and Forecast to 2028

July 5, 2022 | investing.com

World Holdings Co Ltd (2429)

June 4, 2022 | finanznachrichten.de

Beroe Inc.: Beroe partners with Mintec to power its intelligence offering with market-leading commodity price data

See More Headlines

Receive NTEC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Intec Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 5/17/2021
Today: 4/19/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical Preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:NTEC
CUSIP: N/A
CIK: 1638381
Web: www.intecpharma.com
Phone: (722) 586-4657
Fax: N/A
Employees: 40
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($16.32)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-14,130,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -96.37%
Return on Assets: -68.87%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.34
Quick Ratio: 2.34

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $16.18 per share
Price / Book: N/A

Miscellaneous

Outstanding Shares: 898,000
Free Float: N/A
Market Cap: $8.65 million
Optionable: Optionable
Beta: 0.83

7 Stocks to Own Before the 2024 Election

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

Jeffrey A. Meckler
Vice Chairman & Chief Executive Officer
Nir Sassi
President & Chief Financial Officer
Michael James Newman
Director & Chief Scientific Officer
Anna Hotovely-Salomon
Director-Clinical Affairs
Walt A. Linscott
Chief Business Officer

Key Competitors

View All Competitors

NTEC Stock Analysis - Frequently Asked Questions

How were Intec Pharma's earnings last quarter?: Intec Pharma Ltd (NASDAQ:NTEC) announced its quarterly earnings data on Monday, May, 17th. The biotechnology company reported ($3.84) earnings per share for the quarter, missing the consensus estimate of ($3.48) by $0.36.
When did Intec Pharma's stock split?: Shares of Intec Pharma reverse split on Tuesday, July 27th 2021. The 1-4 reverse split was announced on Tuesday, July 27th 2021. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, July 27th 2021. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split.
What other stocks do shareholders of Intec Pharma own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Intec Pharma investors own include SCYNEXIS (SCYX), Inovio Pharmaceuticals (INO), Dynavax Technologies (DVAX), Nabriva Therapeutics (NBRV), Onconova Therapeutics (ONTX), Viking Therapeutics (VKTX), Allena Pharmaceuticals (ALNA), T2 Biosystems (TTOO) and Acasti Pharma (ACST).
When did Intec Pharma IPO?: Intec Pharma (NTEC) raised $30 million in an IPO on Tuesday, August 4th 2015. The company issued 5,000,000 shares at a price of $6.00 per share. Maxim Group and Roth Capital Partners acted as the underwriters for the IPO.

This page (NASDAQ:NTEC) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Intec Pharma (NTEC) Stock Price, News & Analysis

About Intec Pharma Stock (NASDAQ:NTEC)

NTEC Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

NTEC Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info